表紙
市場調査レポート

中国の医薬品市場:商業的・戦略的発展

The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024

発行 GMR Data Ltd 商品コード 301556
出版日 ページ情報 英文 160 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
中国の医薬品市場:商業的・戦略的発展 The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024
出版日: 2014年03月19日 ページ情報: 英文 160 Pages
概要

中国のOTC医薬品市場は2008年の110億米ドルから成長し、2013年に206億米ドルへ達しました。中国における医薬品売上の成長は、同国の経済成長に基づいています。国民1人当たりの医療費は、2008年の157米ドルから2011年には278米ドルへ増加しました。中国政府は医療サービスインフラを改善するため、2012年に39億米ドルを投資しました。中国では年間、患者1人あたりの糖尿病治療に平均で190米ドルが費やされています。2030年までに中国の糖尿病コストは年間280億米ドルになると予測されています。中国の総人口に占める65歳以上の人口の割合は2008年の8.3%から2011年には9.1%へ増加しています。

当レポートは、中国の医薬品市場について調査し、市場における現況、動向、機会、および規制環境の分析、市場予測、医療装置セグメント別の分析、治療セグメント別の分析、および主要企業のプロファイルなどを提供しており概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 中国の医薬品市場における促進因子・阻害因子

  • 人口の高齢化が中国における医薬品市場の成長を後押し
  • 中国における都市化の拡大
  • 医療費の増加が中国における医薬品需要を増加させる
  • 中国におけるMNC向けの政府政策と環境の変化
  • 薬剤品質の改善を求める需要の増加
  • 中国における医療制度改革
  • 中国における医療民営化への道
  • 中国における医薬品流通産業の統合
  • ライフスタイルに関連した病気の増加
  • バイオテクノロジー市場:中国向けの戦略的産業
  • GMPへのフォーカスが品質・コンプライアンスの改革を導く
  • 政府主導のイニシアチブが外国企業を惹きつける
  • 人材プールの利用可能性
  • 創薬アウトソーシングの増加が中国のCRO市場を活気づける
  • 規制環境
  • 伝統中国医学

第3章 中国の医薬品市場予測

  • 中国の医薬品市場:医薬品売上(OTC・処方薬市場)
  • 中国の特許薬市場
  • 中国の医薬品販売市場:処方薬・OTC薬の売上

第4章 中国の医療装置市場

  • 中国における医療装置市場の概要
  • 中国の医療装置市場:診断画像セグメント
  • 中国の医療装置市場:患者用補助器具セグメント
  • 中国の医療装置市場:消耗品セグメント
  • 中国の医療装置市場:歯科セグメント
  • 中国の医療装置市場:整形外科セグメント
  • 医療装置市場における課題・機会
  • 中国の医療装置市場:企業の情勢
  • 中国の医療装置市場における主な国内企業

第5章 中国のAPI市場

  • APIの概要
  • 中国のAPI市場における主な成長促進因子
  • 主な課題
  • 中国のAPI市場:企業情勢

第6章 主な中国の治療市場

  • 心疾患
  • 感染症
  • がん
  • 神経系
  • 消化管・代謝

第7章 主要企業

  • Pfizer
  • Bayer
  • Sanofi-Aventis
  • AstraZeneca
  • Roche
  • Merck and Co.
  • Novartis
  • GSK
  • Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)

第8章 専門家の見解

図表リスト

目次
Product Code: CHI1
  • Capture or increase your foothold in the Chinese market TODAY
  • Establish partnerships to manufacture, distribute or develop Chinese products
  • Establish anti-counterfeiting systems today to increase market size and revenue

From 2008 to 2013, China's OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up from to $11bn in 2008 - but what will it be this year? Next year? And in 5 years time?

The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access - and this is only the OTC market - what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

China's pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?

Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world's diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types - your company must capture a segment of this market TODAY.

Anti-Counterfeiting and anti-corruption - How the Chinese market is changing Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

Increased inward investment from multiple 'Big Pharma' companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.

Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.

  • Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011
  • Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015
  • In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure.
  • Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases
  • The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008

This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment.

Discover exactly what the industry leaders are doing TODAY -

Industry information sourced exclusively for this report. This information is not available anywhere else

Utilising primary and secondary research sources, GMR Data have interviewed leading specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations specialising in access to the Chinese market, as well as Chinese pharmaceutical companies accessing the global market. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field - This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all pharma sectors and why all stakeholders demand development of the Chinese pharmaceutical market. This report will arm you with all you and your company require to develop, price, launch and market a product in China, or compete with a Chinese product launched in your market.

With over 160 pages, and over 140+ charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Table of Contents

1. Executive Summary

  • 1.1. Chinese Pharmaceutical Market Review
  • 1.2. Chapter Breakdown
  • 1.3. Research and Analysis Methods

2. Drivers & Restraints of the Chinese Pharmaceutical Market

  • 2.1 An Ageing Population will drive pharmaceutical market growth in China
  • 2.2 Increase in Chinese urbanisation
  • 2.3 Increase in Healthcare expenditure will increase drug demand in China
  • 2.4 Government policies and changing environment for MNCs in China
  • 2.5 Increased demand for improved drug quality
  • 2.6 Healthcare Reform in China
  • 2.7 Path to privatization of Chinese healthcare
  • 2.8 Consolidation of the pharmaceutical distribution industry in China
  • 2.9 Increase in lifestyle related diseases
  • 2.10 Biotechnology Market: The Strategic Industry for China
  • 2.11 Focus on GMP leads to Quality and Compliance reforms
  • 2.12 Government led initiatives to attract foreign players
  • 2.13 Talent Pool Availability
  • 2.14 Increased Outsourcing of Drug Discovery boosting the Chinese CRO Market
  • 2.15 Regulatory Environment
    • 2.15.1 Drug filing
    • 2.15.2 Advertisements
    • 2.15.3 Drugs Pricing & Reimbursement
  • 2.16 Traditional Chinese Medicine

3. China Pharmaceutical Market Forecast

  • 3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and Prescription market)
    • 3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024
    • 3.1.2 China Pharmaceutical Sales Market by Generic and Patented Drug Sales
    • 3.1.3 Generic Drugs Market in China
  • 3.2 The Chinese Patented Drugs Market
  • 3.3 China Pharmaceutical Sales Market by Prescription and OTC Drug Sales
    • 3.3.1 Prescription Drug Market in China
    • 3.3.2 Over-the-Counter Drugs Market in China

4. The Chinese Medical Device Market

  • 4.1 Overview of the Medical Device Market in China
  • 4.2 China Medical Devices Market: Diagnostic Imaging Segment
  • 4.3 China Medical Devices Market: Patient Aids Segment
  • 4.4 China Medical Devices Market: Consumables Segment
  • 4.5 The China Medical Devices Market: Dental Segment
  • 4.6 China Medical Devices Market: Orthopaedic Segment
  • 4.7 Challenges & Opportunities in the Medical devices market
    • 4.7.1 Opportunities
    • 4.7.2 Challenges
  • 4.8 China Medical Devices Market: Players Landscape
    • 4.8.1 Multinational Corporations in the Chinese Medical devices market
    • 4.8.1.1 General Electric Healthcare
      • 4.8.1.1 Medtronic, Inc.
      • 4.8.1.2 Zimmer - Zimmer Holdings, Inc.
      • 4.8.1.3 Stryker Corporation
      • 4.8.1.4 Siemens Healthcare
      • 4.8.1.5 Johnson & Johnson
      • 4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd
  • 4.9 Key Domestic companies in the Chinese Medical devices market
    • 4.9.1 Weigao group
    • 4.9.2 Mindray Medical International Limited
    • 4.9.3 MicroPort Scientific Corporation
    • 4.9.4 Biosensors International Group, Ltd

5. The Chinese API Market

  • 5.1 API Overview
    • 5.1.1 Global API Market
      • 5.1.1.1 APAC API Market
      • 5.1.1.2 The Chinese API Market
  • 5.2 Major Growth Drivers for the Chinese API Market
  • 5.3 Key Challenges
  • 5.4 China API Market: Players Landscape
    • 5.4.1 Major Chinese API Manufacturers
      • 5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd
      • 5.4.1.2 Jiangsu Hengrui Medicine Co., Ltd
      • 5.4.1.3 CSPC Pharmaceutical Group Limited
      • 5.4.1.4 Shandong Xinhua Pharmaceutical Company Limited
      • 5.4.1.5 Shanghai Pharma Holding Company Limited
      • 5.4.1.6 North China Pharmaceutical Group Corp.

6 Key Chinese Therapeutic Markets

  • 6.1 Cardiovascular Diseases
    • 6.1.1 Chinese Cardiovascular Disease treatments market forecast 2014-2024
    • 6.2 Infectious Diseases
  • 6.2.1 Chinese Infectious Disease treatments market forecast 2014-2024
  • 6.3 Oncology
    • 6.3.1 Chinese Oncology treatments market forecast 2014-2024
  • 6.4 Nervous System
    • 6.4.1 The Chinese Nervous System market forecast 2014-2024
  • 6.5 Alimentary Tract & Metabolism
    • 6.5.1 The Chinese Alimentary Tract & Metabolism treatments market forecast 2014-2024

7. Major Players

  • 7.1 Pfizer
  • 7.2. Bayer
  • 7.3. Sanofi-Aventis
  • 7.4. AstraZeneca
  • 7.5. Roche
  • 7.6. Merck and Co.
  • 7.7. Novartis
  • 7.8. GSK
  • 7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)

8. Expert Opinion

  • 8.1 Dr Cezary Statuch - Vice President Bristol-Myers Squibb, China
  • 8.2 Dr Eugene Buff - Primary Care Innovation Consulting & UsTech Discovery LLC

List of Tables

  • Table 2.1.1: Percentage of Chinese population aged 60 and over / 65 and over in 2000, 2011 & 2016
  • Table 2.1.2: Health spending in China, India and the US, 2009 & 2011 ($/p/a & percentage change)
  • Table 2.1.3: Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011
  • Table 2.1.4: Life expectancy; Selected Countries 2004 to 2011
  • Table 2.2.1 Medical Coverage for Rural / Urban inhabitants in China 2006 / 2009 (million people)
  • Table 2.2.2: Major cities in China by population (2011)
  • Table 2.3.1 China's Health Care Expenditure Per Capita 2003-2011
  • Table 2.6.1: Key New Drugs on the 2012 Essential Drugs List
  • Table 2.8.1: Total Revenue of Key Chinese Pharmaceutical Distribution Companies, 2012 ($/bn)
  • Table 2.9.1: Number of Patients with Diabetes in China
  • Table 2.15.3.1 China healthcare payment source breakdown 2000, 2005 & 2010 (%)
  • Table 3.1.1.1: China Pharmaceutical Sales Market Size: 2008-2013 ($bn)
  • Table 3.1.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)
  • Table 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013
  • Table 3.1.3.2: China's Generic Drug Sales Market Forecast 2014-2024 ($bn)
  • Table 3.2.1: China Parented Drug Sales Market Size: 2008-2013
  • Table 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($bn)
  • Table 3.3.1.1: China Prescription Drugs Sales Market Size: 2008-2013
  • Table 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024
  • Table 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013
  • Table 3.3.2.2 China's OTC Drug Sales Percentage 2013
  • Table 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024
  • Table 4.a: The Chinese Medical Devices Market Forecast 2014 -2024, by device type ($/bn)
  • Table 4.b: Key Device Segments CAGR 2014-2024 (%)
  • Table 4.c: Estimated China Medical Devices Market Share for Selected Segments 2014, 2019 and 2024 (%)
  • Table 4.1.1: China Medical Devices Market Size: 2008-2013
  • Table 4.1.2: China Medical Devices Export Market 2009-2011 ($/bn)
  • Table 4.1.3: China Medical Devices Import Market
  • Table 4.1.4: China Medical Devices Market Forecast 2014-2024 ($bn)
  • Table 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013 ($/bn)
  • Table 4.2.2: China Medical Devices Market: Diagnostic Imaging Segment Forecast 2014-2024 ($/bn)
  • Table 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)
  • Table 4.3.2: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)
  • Table 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013 ($/bn)
  • Table 4.4.2: The Chinese Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)
  • Table 4.5.1: China Medical Devices Market: Dental Segment 2008-2013
  • Table 4.5.2: China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)
  • Table 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013
  • Table 4.6.2: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)
  • Table 5.1: China API Market Forecast 2014 -2024, compared to Global API Market ($ bn)
  • Table 5.1.1.: China API Market Size: 2009-2013
  • Table 5.1.2: China API Market Forecast 2014-2024 ($bn)
  • Table 6.a: China Pharmaceutical Market by Therapeutic Areas 2014 -2024, ($ bn)
  • Table 6.b: Key Therapeutic Areas CAGR 2014-2024 (%)
  • Table 6.c: Estimated China Pharmaceutical Market Share by Therapeutic Areas - 2014, 2019 and 2024 (%)
  • Table 6.1.1: Cardiovascular Disease Incidence China 2010 - 2013
  • Table 6.1.2: Deaths due to Cardiovascular Disease in India, China and Developed Markets
  • Table 6.1.3: China Pharmaceutical Market for Cardiovascular Disease, 2008 - 2013 ($/bn)
  • Table 6.1.4: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 - 2024
  • Table 6.2.1: Infectious Disease Incidence 2010 - 2013
  • Table 6.2.2: Infectious Disease Mortality 2010 - 2013
  • Table 6.2.3: China Pharmaceutical Market for Systemic Anti-Infective, 2008 - 2013
  • Table 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 - 2024
  • Table 6.3.1: Cancer Incidence China 2010 - 2013
  • Table 6.3.2: Cancer Mortalities 2010 - 2013
  • Table 6.3.3: China Pharmaceutical Market for Oncology, 2008 - 2013
  • Table 6.3.4: China Pharmaceutical Market for Oncology: Forecast 2014 - 2024
  • Table 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 - 2013
  • Table 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 - 2024
  • Table 6.5.1: China Pharmaceutical Market for Metabolism, 2008 - 2013
  • Table 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 - 2024

List of Figures

  • Figure 2.1.1: China population growth trend 1950-2013
  • Figure 2.1.2: Projected comparison of China's population vs. other heavily populated countries 2016 (million people)
  • Figure 2.1.3: China's Age distribution: 2001 to 2011
  • Figure 2.1.4: Life expectancy in China
  • Figure 2.2.1: China's Rural and Urban population from 1990 to 2025 - Billion People
  • Figure 2.2.2: China's Urbanisation Rate 1990-2025 (%)
  • Figure 2.2.3: Per Capita Disposable Income
  • Figure 2.3.1: China GDP growth trend (2004 - 2012)
  • Figure 2.3.2: China's total health expenditure (as % of GDP): 2004 to 2011
  • Figure 2.3.3: China healthcare expenditure per capita growth trend (2003 - 2011)
  • Figure 2.6.1: China's 2009 health care reform - Healthcare package breakdown
  • Figure 2.8.1: Chinese pharmaceutical distribution sales: 2006 to 2012
  • Figure 2.9.1: Number of Patients with Diabetes in 2013 - Globally (million people)
  • Figure 2.13.1: China's talent pool in 2010- (in millions)
  • Figure 2.15.3.1: China healthcare payment source breakdown
  • Figure 3.1.1: China Pharmaceutical Sales Market Size: 2008-2013
  • Figure 3.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 ($bn)
  • Figure 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013
  • Figure 3.1.3.2: China's Generic Drug Sales Market Forecast 2014-2024 ($ bn)
  • Figure 3.2.1: China Patented Drug Sales Market Size: 2008-2013
  • Figure 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 ($ bn)
  • Figure 3.3.1.1: China Prescription Drug Sales Market Size: 2008-2013
  • Figure 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024
  • Figure 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013
  • Figure 3.3.2.2 OTC drugs Channel Breakdown in China 2011
  • Figure 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024
  • Figure 4.a: China Medical Devices Market Share for Selected Segments 2014
  • Figure 4.b: China Medical Devices Market Share for Selected Segments 2019
  • Figure 4.c: China Medical Devices Market Share for Selected Segments 2024
  • Figure 4.1.1: China Medical Devices Market Size: 2008-2013
  • Figure 4.1.2: China Medical Devices Market Forecast 2014-2024 ($bn)
  • Figure 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013
  • Figure 4.2.2: China Diagnostic Imaging devices breakdown by sub-segment, 2012 (%)
  • Figure 4.2.3: China Medical Devices Market: Diagnostics Segment Forecast 2014-2024 ($bn)
  • Figure 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 ($/bn)
  • Figure 4.3.2: 2012 Patient Aids devices breakdown by sub-segment 2012 (%)
  • Figure 4.3.3: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 ($/bn)
  • Figure 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013
  • Figure 4.4.2: 2012 Consumables devices breakdown by sub-segment
  • Figure 4.4.3: China Medical Devices Market: Consumables Segment Forecast 2014-2024 ($ bn)
  • Figure 4.5.1: China Medical Devices Market: Dental Segment 2008-2013
  • Figure 4.5.2: 2012 Dental Devices breakdown by sub-segment, China, 2013
  • Figure 4.5.3: China Medical Devices Market: Dental Segment Forecast 2014-2024 ($m)
  • Figure 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013
  • Figure 4.6.2: 2012 Orthopaedic Devices breakdown by sub-segment
  • Figure 4.6.3: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 ($m)
  • Figure 4.8.1.2.1: Medtronic 2012 Customer base breakdown by region
  • Figure 4.9.1.1: 2012 Customer base breakdown by segment
  • Figure 4.9.1.2: 2012 Sales revenue breakdown by region
  • Figure 4.9.1.3: Weigao Group Sales revenue breakdown by product segment 2012 (%)
  • Figure 4.9.2.1: 2012 Sales revenue breakdown by region
  • Figure 4.9.2.2: 2012 Sales revenue breakdown by product
  • Figure 4.9.3.1: 2012 Sales revenue breakdown by product (%)
  • Figure 4.9.4.1: 2012 Sales revenue breakdown by product (%)
  • Figure 5.1.1.1: Breakdown of API Manufacturing 2012
  • Figure 5.1.1.2.1: China API Market Size: 2009-2013
  • Figure 5.1.1.2.2: China API Market Breakdown 2013
  • Figure 5.1.1.2.3: China API Market Forecast 2014-2024 ($bn)
  • Figure 6.a: China Pharmaceutical Market Share by Therapeutic Areas 2014
  • Figure 6.b: China Pharmaceutical Market Share by Therapeutic Areas 2019
  • Figure 6.c: China Pharmaceutical Market Share by Therapeutic Areas 2024
  • Figure 6.1.1: Cardiovascular Disease Incidence 2010 - 2013
  • Figure 6.1.2: China Pharmaceutical Market for Cardiovascular Disease, 2008 - 2013 ($/bn)
  • Figure 6.1.3: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 - 2024
  • Figure 6.2.1: Infectious Disease Incidence 2010 - 2013
  • Figure 6.2.2: Infectious Disease Mortality 2010 - 2013
  • Figure 6.2.3: Mortality as per Infectious Diseases, China 2012
  • Figure 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective, 2008 - 2013
  • Figure 6.2.5: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 - 2024
  • Figure 6.3.1: Cancer Deaths in China / Hong Kong, 2011
  • Figure 6.3.2: China Pharmaceutical Market for Oncology, 2008 - 2013
  • Figure 6.3.3: China Pharmaceutical Market for Oncology: Forecast 2014 - 2024
  • Figure 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 - 2013
  • Figure 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 - 2024
  • Figure 6.5.1: China Pharmaceutical Market for Metabolism, 2008 - 2013
  • Figure 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 - 2024
  • Figure 7.9.1 Novo Nordisk's sales of diabetes products in China, 2012Contents
Back to Top